<p>Evelyn Partners Investment Management LLP 在第二季度减少了对强生公司（NYSE:JNJ - 免费报告）11.0% 的持仓，根据其最近向 SEC 的披露。该基金在此期间出售了 13,850 股后，持有 112,275 股该公司的股票。强生公司约占 Evelyn Partners Investment Management LLP 投资组合的 0.9%，使其成为该基金第 27 大持股。Evelyn Partners Investment Management LLP 在强生公司的持股在最近一个季度末价值为 18,932,000 美元。</p>
<ul>
<li>为什么 GRAIL 股票可能成为生物科技的下一个重大突破</li>
</ul>
<p>其他对冲基金和机构投资者也对该公司的持仓进行了调整。Brighton Jones LLC 在第四季度将其在强生公司的股份增加了 13.9%。Brighton Jones LLC 现在持有 51,876 股该公司的股票，价值 7,502,000 美元，此前在上个季度购买了 6,332 股。Wealth Group Ltd.在第一季度购买了强生公司的新股份，价值约 218,000 美元。Smart Money Group LLC 在第一季度将其在强生公司的持股增加了 6.5%。Smart Money Group LLC 现在持有 6,687 股该公司的股票，价值 1,109,000 美元，此前在上个季度购买了 407 股。United Bank 在第一季度将其在强生公司的持仓增加了 110.7%。United Bank 现在持有 9,279 股该公司的股票，价值 1,539,000 美元，此前在上个季度购买了 4,876 股。最后，Noesis Capital Mangement Corp 在第一季度将其在强生公司的持股增加了 12.0%。Noesis Capital Mangement Corp 现在持有 9,031 股该公司的股票，价值 1,498,000 美元，此前在上个季度购买了 971 股。机构投资者和对冲基金持有该公司 69.55% 的股票。</p>
<p>获取 <strong>强生公司</strong> 的提醒：</p>
<h2>内部活动</h2>
<p>在其他消息中，执行副总裁 Jennifer L. Taubert 于 9 月 4 日星期四出售了 56,471 股该公司的股票。股票以 177.81 美元的平均价格出售，总交易额为 10,041,108.51 美元。交易完成后，该执行副总裁持有 178,013 股该公司的股票，价值约 31,652,491.53 美元。这代表其持股减少了 24.08%。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。公司内部人士持有该公司 0.16% 的股票。</p>
<h2>强生股票上涨 0.4%</h2>
<ul>
<li>3 只适合不安市场的聪明防御性股票</li>
</ul>
<p>强生股票在周五开盘价为 203.88 美元。该公司的市值为 4912.1 亿美元，市盈率为 19.68，PEG 比率为 2.19，贝塔值为 0.38。强生公司的 1 年最低价为 140.68 美元，1 年最高价为 206.94 美元。该公司的 50 日移动平均价格为 188.25 美元，200 日移动平均价格为 171.55 美元。该公司的债务与股本比率为 0.50，流动比率为 1.07，速动比率为 0.80。</p>
<p>强生公司（NYSE:JNJ - 获取免费报告）最近一次发布财报是在 8 月 30 日星期三。该公司报告本季度每股收益为 2.26 美元。该季度的收入为 240.2 亿美元。强生公司的股本回报率为 32.73%，净利润率为 27.26%。研究分析师预测强生公司在当前年度的每股收益将达到 10.58 美元。</p>
<h2>强生公司分红公告</h2>
<ul>
<li>持有评级，高回报？3 只可能超出预期的股票</li>
</ul>
<p>该公司最近还宣布了一项季度分红，将于 12 月 9 日星期二支付。11 月 25 日的股东将获得 1.30 美元的分红。这相当于年化 5.20 美元的分红，收益率为 2.6%。除息日为 11 月 25 日。强生公司的分红支付比率（DPR）目前为 50.19%。</p>
<h2>分析师设定新目标价</h2>
<p>一些分析师最近对该公司进行了评论。Scotiabank 在 11 月 13 日星期四的研究报告中开始覆盖强生公司。他们对该股票设定了 “行业表现优于大盘” 的评级和 230.00 美元的目标价。华尔街 Zen 在 9 月 13 日星期六将强生公司的评级从 “持有” 上调至 “买入”。Sanford C. Bernstein 在 10 月 6 日星期一将强生公司的目标价从 172.00 美元上调至 193.00 美元，并给予该公司 “市场表现” 的评级。摩根士丹利在 10 月 15 日星期三设定了强生公司的 190.00 美元目标价。最后，Cowen 在 10 月 14 日星期二的研究报告中重申了对强生公司的 “买入” 评级。四位投资分析师对该股票给予了强烈买入评级，十三位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 201.05 美元。</p>
<p><strong>阅读我们关于强生公司的最新股票报告</strong></p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生公司是一家控股公司，专注于医疗领域的产品研究、开发、生产和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过强生公司</li>
<li>最佳航空航天股票投资</li>
<li>MarketBeat 周评 – 11/17 - 11/21</li>
<li>即将到来的 IPO 股票锁定期，解释</li>
<li>一个宏伟的 AI 投资？Stanley Druckenmiller 的最新科技动态</li>
<li>什么是分红冠军？如何投资于冠军</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
</ul>
<p><strong>想知道其他对 JNJ 持有何种投资的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取最新的 13F 文件和强生（NYSE:JNJ - 免费报告）的内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Evelyn Partners Investment Management LLP 在第二季度减少了对强生的持股，减幅为 11%，目前持有 112,275 股，价值 1893 万美元。其他投资者也调整了他们的持仓，Brighton Jones LLC 增加了 13.9% 的持股。执行副总裁 Jennifer L. Taubert 出售了 56,471 股，持股比例下降了 24.08%。强生股票开盘价为 203.88 美元，市值为 4912.1 亿美元。分析师预测今年每股收益为 10.58，并设定了新的价格目标，其中包括由加拿大丰业银行设定的 230 美元目标</p>

<p>Evelyn Partners Investment Management LLP decreased its position in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 11.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 112,275 shares of the company's stock after selling 13,850 shares during the period. Johnson &amp; Johnson comprises approximately 0.9% of Evelyn Partners Investment Management LLP's portfolio, making the stock its 27th biggest holding. Evelyn Partners Investment Management LLP's holdings in Johnson &amp; Johnson were worth $18,932,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Evelyn Partners Investment Management LLP 在第二季度减少了对强生公司（NYSE:JNJ - 免费报告）11.0% 的持仓，根据其最近向 SEC 的披露。该基金在此期间出售了 13,850 股后，持有 112,275 股该公司的股票。强生公司约占 Evelyn Partners Investment Management LLP 投资组合的 0.9%，使其成为该基金第 27 大持股。Evelyn Partners Investment Management LLP 在强生公司的持股在最近一个季度末价值为 18,932,000 美元。</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能成为生物科技的下一个重大突破</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC grew its position in shares of Johnson &amp; Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Wealth Group Ltd. purchased a new stake in Johnson &amp; Johnson in the 1st quarter valued at approximately $218,000. Smart Money Group LLC grew its holdings in Johnson &amp; Johnson by 6.5% during the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company's stock valued at $1,109,000 after buying an additional 407 shares during the last quarter. United Bank increased its position in Johnson &amp; Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company's stock worth $1,539,000 after buying an additional 4,876 shares in the last quarter. Finally, Noesis Capital Mangement Corp raised its holdings in shares of Johnson &amp; Johnson by 12.0% in the first quarter. Noesis Capital Mangement Corp now owns 9,031 shares of the company's stock worth $1,498,000 after acquiring an additional 971 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者也对该公司的持仓进行了调整。Brighton Jones LLC 在第四季度将其在强生公司的股份增加了 13.9%。Brighton Jones LLC 现在持有 51,876 股该公司的股票，价值 7,502,000 美元，此前在上个季度购买了 6,332 股。Wealth Group Ltd.在第一季度购买了强生公司的新股份，价值约 218,000 美元。Smart Money Group LLC 在第一季度将其在强生公司的持股增加了 6.5%。Smart Money Group LLC 现在持有 6,687 股该公司的股票，价值 1,109,000 美元，此前在上个季度购买了 407 股。United Bank 在第一季度将其在强生公司的持仓增加了 110.7%。United Bank 现在持有 9,279 股该公司的股票，价值 1,539,000 美元，此前在上个季度购买了 4,876 股。最后，Noesis Capital Mangement Corp 在第一季度将其在强生公司的持股增加了 12.0%。Noesis Capital Mangement Corp 现在持有 9,031 股该公司的股票，价值 1,498,000 美元，此前在上个季度购买了 971 股。机构投资者和对冲基金持有该公司 69.55% 的股票。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生公司</strong> 的提醒：</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Jennifer L. Taubert 于 9 月 4 日星期四出售了 56,471 股该公司的股票。股票以 177.81 美元的平均价格出售，总交易额为 10,041,108.51 美元。交易完成后，该执行副总裁持有 178,013 股该公司的股票，价值约 31,652,491.53 美元。这代表其持股减少了 24.08%。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。公司内部人士持有该公司 0.16% 的股票。</p>
</div><h2>Johnson &amp; Johnson Stock Up 0.4%</h2>
<div class="lb-trans"><h2>强生股票上涨 0.4%</h2>
</div><ul>
<li>3 Smart Defensive Stocks for an Uneasy Market</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只适合不安市场的聪明防御性股票</li>
</ul>
</div><p>JNJ stock opened at $203.88 on Friday. The firm has a market cap of $491.21 billion, a price-to-earnings ratio of 19.68, a PEG ratio of 2.19 and a beta of 0.38. Johnson &amp; Johnson has a 1-year low of $140.68 and a 1-year high of $206.94. The firm has a fifty day moving average price of $188.25 and a two-hundred day moving average price of $171.55. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.</p>
<div class="lb-trans"><p>强生股票在周五开盘价为 203.88 美元。该公司的市值为 4912.1 亿美元，市盈率为 19.68，PEG 比率为 2.19，贝塔值为 0.38。强生公司的 1 年最低价为 140.68 美元，1 年最高价为 206.94 美元。该公司的 50 日移动平均价格为 188.25 美元，200 日移动平均价格为 171.55 美元。该公司的债务与股本比率为 0.50，流动比率为 1.07，速动比率为 0.80。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%. Research analysts predict that Johnson &amp; Johnson will post 10.58 EPS for the current year.</p>
<div class="lb-trans"><p>强生公司（NYSE:JNJ - 获取免费报告）最近一次发布财报是在 8 月 30 日星期三。该公司报告本季度每股收益为 2.26 美元。该季度的收入为 240.2 亿美元。强生公司的股本回报率为 32.73%，净利润率为 27.26%。研究分析师预测强生公司在当前年度的每股收益将达到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>强生公司分红公告</h2>
</div><ul>
<li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li>
</ul>
<div class="lb-trans"><ul>
<li>持有评级，高回报？3 只可能超出预期的股票</li>
</ul>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson &amp; Johnson's dividend payout ratio (DPR) is presently 50.19%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 12 月 9 日星期二支付。11 月 25 日的股东将获得 1.30 美元的分红。这相当于年化 5.20 美元的分红，收益率为 2.6%。除息日为 11 月 25 日。强生公司的分红支付比率（DPR）目前为 50.19%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of analysts recently commented on the company. Scotiabank initiated coverage on Johnson &amp; Johnson in a research note on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $230.00 price objective on the stock. Wall Street Zen upgraded Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, September 13th. Sanford C. Bernstein raised their price target on shares of Johnson &amp; Johnson from $172.00 to $193.00 and gave the company a &#34;market perform&#34; rating in a report on Monday, October 6th. Morgan Stanley set a $190.00 price objective on Johnson &amp; Johnson in a research note on Wednesday, October 15th. Finally, Cowen restated a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a research note on Tuesday, October 14th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $201.05.</p>
<div class="lb-trans"><p>一些分析师最近对该公司进行了评论。Scotiabank 在 11 月 13 日星期四的研究报告中开始覆盖强生公司。他们对该股票设定了 “行业表现优于大盘” 的评级和 230.00 美元的目标价。华尔街 Zen 在 9 月 13 日星期六将强生公司的评级从 “持有” 上调至 “买入”。Sanford C. Bernstein 在 10 月 6 日星期一将强生公司的目标价从 172.00 美元上调至 193.00 美元，并给予该公司 “市场表现” 的评级。摩根士丹利在 10 月 15 日星期三设定了强生公司的 190.00 美元目标价。最后，Cowen 在 10 月 14 日星期二的研究报告中重申了对强生公司的 “买入” 评级。四位投资分析师对该股票给予了强烈买入评级，十三位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 201.05 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于强生公司的最新股票报告</strong></p>
</div><h2>Johnson &amp; Johnson Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生公司是一家控股公司，专注于医疗领域的产品研究、开发、生产和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Best Aerospace Stocks Investing</li>
<li>MarketBeat Week in Review – 11/17 - 11/21</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过强生公司</li>
<li>最佳航空航天股票投资</li>
<li>MarketBeat 周评 – 11/17 - 11/21</li>
<li>即将到来的 IPO 股票锁定期，解释</li>
<li>一个宏伟的 AI 投资？Stanley Druckenmiller 的最新科技动态</li>
<li>什么是分红冠军？如何投资于冠军</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 JNJ 持有何种投资的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取最新的 13F 文件和强生（NYSE:JNJ - 免费报告）的内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Evelyn Partners Investment Management LLP 减少了在强生公司 $JNJ 的持仓